ZNTL Smart Money
Zentalis Pharmaceuticals, Inc.
1W: -17.1%
1M: -23.9%
3M: -57.6%
YTD: +44.5%
1Y: +15.8%
3Y: -89.0%
5Y: -97.4%
$1.98
-0.09 (-4.35%)
Pre-Market: $1.85 (-0.12, -6.31%)
Weekly Expected Move ±11.3%
$2
$2
$2
$2
$3
Credit Risk of going bust: higher than 80% of companies Debt: 21.1% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the third-riskiest tenth, about 1 in 140 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.03 (down 99%), Zentalis Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $37.7M against a stock market value of $140.9M.
Distance to default 2.58 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $4.1M (short-term plus half of long-term), stock volatility 117.5%; Altman Z'' -18.17. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.03 (down 99%), Zentalis Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $37.7M against a stock market value of $140.9M.
Distance to default 2.58 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $4.1M (short-term plus half of long-term), stock volatility 117.5%; Altman Z'' -18.17. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
🏦 Institutional Activity
Latest: Q2 2026136
Institutions Holding
+26 vs prior
153.6%
Ownership
+65.49%
37
New
28
Increased
51
Reduced
19
Closed
👔 Insider Trades
25 records| Date | Name | Title | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-30 | Bruns Ingmar | officer: chief medical officer | A-Grant/Award | 9,727 | $2.18 | $21K | Filing |
| 2026-08-14 | WALTERS GROUP | 10% owner | P-Purchase | 4,335,000 | $3.50 | $15.2M | Filing |
| 2026-08-14 | WALTERS WILLIAM THURMAN | 10% owner | P-Purchase | 4,335,000 | $3.50 | $15.2M | Filing |
| 2026-08-14 | WALTERS SUSAN BERKLEY | 10% owner | P-Purchase | 4,335,000 | $3.50 | $15.2M | Filing |
| 2026-06-16 | Skvarka Jan | director | A-Grant/Award | 57,100 | $— | $0 | Filing |
| 2026-06-16 | Kariuki Enoch | director | A-Grant/Award | 57,100 | $— | $0 | Filing |
| 2026-06-16 | Myers Scott Dunseth | director | A-Grant/Award | 57,100 | $— | $0 | Filing |
| 2026-06-16 | Walker Luke Nathaniel | director | A-Grant/Award | 57,100 | $— | $0 | Filing |
| 2026-06-16 | Johnson David Michael | director | A-Grant/Award | 57,100 | $— | $0 | Filing |
| 2026-05-26 | Campbell Shannon | director | A-Grant/Award | 114,200 | $— | $0 | Filing |
| 2026-02-10 | Vultaggio Vincent | officer: pao and pfo | S-Sale | 6,894 | $2.42 | $17K | Filing |
| 2026-02-09 | Bruns Ingmar | officer: chief medical officer | S-Sale | 335 | $2.39 | $802 | Filing |
| 2026-02-09 | EASTLAND JULIA MARIE | officer: ceo & president | S-Sale | 889 | $2.39 | $2K | Filing |
| 2026-02-09 | Vultaggio Vincent | officer: pao and pfo | S-Sale | 3,379 | $2.39 | $8K | Filing |
| 2026-02-06 | Bruns Ingmar | officer: chief medical officer | S-Sale | 2,962 | $2.43 | $7K | Filing |
| 2026-02-06 | EASTLAND JULIA MARIE | officer: ceo & president | S-Sale | 7,866 | $2.43 | $19K | Filing |
| 2026-02-06 | Vultaggio Vincent | officer: pao and pfo | S-Sale | 29,951 | $2.43 | $73K | Filing |
| 2026-02-03 | Vultaggio Vincent | officer: pao and pfo | S-Sale | 556 | $2.52 | $1K | Filing |
| 2026-02-02 | Vultaggio Vincent | officer: pao and pfo | S-Sale | 2,540 | $2.55 | $6K | Filing |
| 2025-12-31 | WALTERS GROUP | 10% owner | P-Purchase | 6,459,973 | $1.20 | $7.8M | Filing |
| 2025-12-31 | WALTERS SUSAN BERKLEY | 10% owner | P-Purchase | 6,459,973 | $1.20 | $7.8M | Filing |
| 2025-12-31 | WALTERS WILLIAM THURMAN | 10% owner | P-Purchase | 6,459,973 | $1.20 | $7.8M | Filing |
| 2025-12-15 | GOEL DAVID E. | 10% owner | S-Sale | 7,500,000 | $1.33 | $10.0M | Filing |
| 2025-12-15 | Matrix Capital Management Company, LP | 10% owner | S-Sale | 7,500,000 | $1.33 | $10.0M | Filing |
| 2025-06-17 | Myers Scott Dunseth | director | A-Grant/Award | 57,603 | $— | $0 | Filing |
🏛️ Congressional Trades
0 records| Date | Politician | Chamber | Type | Amount | Filing |
|---|---|---|---|---|---|
| No congressional trades found | |||||
🏦 Top Institutional Holders
20 holders| Holder | Shares | Value | Date Reported | Filing | |
|---|---|---|---|---|---|
| 5AM Venture Management, LLC | 3,947,913 | $19M | — | 2026-06-30 | Filing |
| BlackRock, Inc. | 3,753,525 | $18M | +2,483,688 | 2026-06-30 | Filing |
| Squadron Capital Management LLC | 3,700,000 | $18M | +69,000 | 2026-06-30 | Filing |
| TWO SIGMA INVESTMENTS, LP | 3,024,936 | $15M | +68,410 | 2026-06-30 | Filing |
| VANGUARD CAPITAL MANAGEMENT LLC | 2,835,669 | $14M | +524,962 | 2026-06-30 | Filing |
| CITADEL ADVISORS LLC | 2,298,403 | $11M | +566,320 | 2026-06-30 | Filing |
| RENAISSANCE TECHNOLOGIES LLC | 1,609,078 | $8M | -329,067 | 2026-06-30 | Filing |
| Opaleye Management Inc. | 1,412,656 | $7M | — | 2026-06-30 | Filing |
| ORBIMED ADVISORS LLC | 1,390,576 | $7M | +1,390,576 | 2026-06-30 | Filing |
| Decheng Capital LLC | 1,323,327 | $6M | — | 2026-06-30 | Filing |
| GEODE CAPITAL MANAGEMENT, LLC | 1,284,117 | $6M | +663,081 | 2026-06-30 | Filing |
| BANK OF AMERICA CORP /DE | 1,114,650 | $5M | -17,644 | 2026-06-30 | Filing |
| Ishara Investments LP | 1,025,000 | $5M | -205,000 | 2026-06-30 | Filing |
| PRIMECAP MANAGEMENT CO/CA | 957,420 | $5M | — | 2026-06-30 | Filing |
| Soleus Capital Management, L.P. | 950,000 | $5M | +950,000 | 2026-06-30 | Filing |
| STATE STREET CORP | 887,416 | $4M | +637,726 | 2026-06-30 | Filing |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 808,548 | $4M | +447,948 | 2026-06-30 | Filing |
| Pfizer Inc | 953,834 | $4M | — | 2026-06-30 | Filing |
| Connor, Clark & Lunn Investment Manageme | 758,033 | $4M | -33,968 | 2026-06-30 | Filing |
| MILLENNIUM MANAGEMENT LLC | 664,281 | $3M | -625,541 | 2026-06-30 | Filing |